Brief: Repare Therapeutics Announces Dosing Of First Patient In Phase 1/2 Clinical Trial Of Rp-3500
29/07/2020 11:12
July 29 (Reuters) - Repare Therapeutics Inc RPTX.O :
* REPARE THERAPEUTICS ANNOUNCES DOSING OF FIRST PATIENT IN
PHASE
1/2 CLINICAL TRIAL OF RP-3500
* REPARE THERAPEUTICS INC - MULTI-CENTER TRIAL WILL EVALUATE
RP-3500 AS A MONOTHERAPY AND IN COMBINATION WITH PFIZER'S PARP
INHIBITOR, TALAZOPARIB
* REPARE THERAPEUTICS- RP-3500 HAS SHOWN SUBSTANTIAL
ANTI-TUMOR
ACTIVITY IN MANY PRECLINICAL MODELS OF SOLID TUMORS AT DOSES
BELOW MAXIMUM TOLERATED DOSE
Source text for Eikon: ID:nBw8XkjhLa
Further company coverage: RPTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Repare Therapeutics
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Repare Therapeutics Announces Acquisition Of Polθ ATPase Inhibitor, RP-3467, By Gilead Sciences For Up To $30 Million In Total Consideration
Brief: Repare Signs Support Agreements With Key Shareholders For Xenotherapeutics Deal
Repare Therapeutics Q2 net loss narrows to $16.7 mln